Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs Standard-dose Epirubicin in Young High-risk DLBCL
NCT03151044Phase 3Unknown
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin in diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
epirubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03151044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151044.